Abstract:Aim: Mitophagy is the regulated process that targets damaged or dysfunctional mitochondria for lysosomal-mediated removal. This process is an essential element of mitochondrial quality control, and dysregulation of mitophagy may contribute to a host of diseases, most notably neurodegenerative conditions such as Parkinson's disease. Mitochondria targeted for mitophagic destruction are molecularly marked by the ubiquitination of several outer mitochondrial membrane (OMM) proteins. This ubiquitination is positively regulated, in part, by the mitochondrial-targeted kinase PINK1 and the E3 ubiquitin ligase Parkin. In contrast, the reverse phenomenon, deubiquitination, removes ubiquitin from Parkin substrates embedded in the OMM proteins, antagonizing mitophagy. Recent evidence suggests that the mitochondrial deubiquitinase USP30 negatively regulates Parkin-mediated mitophagy, providing opportunities to identify USP30 inhibitors and test for their effects in augmenting mitophagy. Here we will characterize a USP30 inhibitor and demonstrate how the pharmacological inhibition of USP30 can augment stress-induced mitophagic flux. Methods: We have conducted mitophagy and mitochondrial analyses in cultured cells. We have determined the plasma pharmacokinetics of the USP30 inhibitor in mice and conducted analyses using the mt-Keima mice to measure in vivo mitophagy directly. Results: The compound has minimal mitochondrial toxicity in cultured cells and is tolerated well in mice. Interestingly, we demonstrated tissue-specific induction of mitophagy following USP30 pharmacological inhibition. In particular, pharmacological inhibition of USP30 induces a significant increase in cardiac mitophagy without detriment to cardiac function. Conclusion: Our data support the evidence that USP30 inhibition may serve as a specific strategy to selectively increase mitophagic flux, allowing for the development of novel therapeutic approaches.

The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy

Beyond Deubiquitylation: USP30-Mediated Regulation of Mitochondrial Homeostasis.

USP30 inhibition induces mitophagy and reduces oxidative stress in parkin-deficient human neurons

Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation

Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin

Deubiquitinating enzyme USP30 negatively regulates mitophagy and accelerates myocardial cell senescence through antagonism of Parkin

Parkin Is Dispensable for Mitochondrial Function, but Its Ubiquitin Ligase Activity Is Critical for Macroautophagy and Neurotransmitters: Therapeutic Potential beyond Parkinson's Disease

Identification of an Autoinhibitory, Mitophagy-Inducing Peptide Derived from the Transmembrane Domain of USP30

USP19 deubiquitinase inactivation regulates α-synuclein ubiquitination and inhibits accumulation of Lewy body-like aggregates in mice

Parkin is recruited selectively to impaired mitochondria and promotes their autophagy

Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor

PP2A forestalls mitophagy by dephosphorylating Parkin and ubiquitin

Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila

A substrate-interacting region of Parkin directs ubiquitination of the mitochondrial GTPase Miro1

Disease-causing mutations in Parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy

Capturing the catalytic intermediates of parkin ubiquitination

Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model

Parkin Mitochondrial Translocation is Achieved Through a Novel Catalytic Activity Coupled Mechanism

Parkin Ubiquitinates Drp1 for Proteasome-Dependent Degradation: Implication of Dysregulated Mitochondrial Dynamics in Parkinson’s Disease

Understanding the Pathogenicity of Parkin Catalytic Domain Mutants

Pharmacological inhibition of USP30 activates tissue-specific mitophagy